Literature DB >> 12734220

Evaluation of the Etest and disk diffusion methods for determining susceptibilities of 235 bloodstream isolates of Candida glabrata to fluconazole and voriconazole.

M A Pfaller1, D J Diekema, L Boyken, S A Messer, S Tendolkar, R J Hollis.   

Abstract

The performances of the Etest and the disk diffusion methods for testing of the susceptibilities of 235 Candida glabrata isolates to fluconazole and voriconazole were compared with that of the National Committee for Clinical Laboratory Standards (NCCLS) approved standard broth microdilution (BMD) method. The NCCLS method used RPMI 1640 broth medium, and MICs were read after incubation for 48 h at 35 degrees C. Etest MICs were determined with RPMI 1640 agar containing 2% glucose (RPG agar) and with Mueller-Hinton agar containing 2% glucose and 0.5 microg of methylene blue per ml (MBE agar) and were read after incubation for 48 h at 35 degrees C. Disk diffusion testing was performed with MBE agar, 25-microg fluconazole disks, and 1- microg voriconazole disks and by incubation at 35 degrees C for 24 h. Overall agreements between the Etest and the BMD MICs obtained with RPG and MBE agars were 91 and 96%, respectively, for fluconazole and 93 and 95%, respectively, for voriconazole. Categorical agreements between the agar-based methods and BMD were 52.3 to 64.7% with fluconazole and 94.8 to 97.4% with voriconazole. The vast majority of the discrepancies by the disk diffusion and Etest methods with fluconazole were minor errors. The agar-based methods performed well in identifying isolates with resistance to fluconazole and decreased susceptibility to voriconazole.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12734220      PMCID: PMC154736          DOI: 10.1128/JCM.41.5.1875-1880.2003

Source DB:  PubMed          Journal:  J Clin Microbiol        ISSN: 0095-1137            Impact factor:   5.948


  16 in total

1.  Comparison of Etest and a tablet diffusion test with the NCCLS broth microdilution method for fluconazole and amphotericin B susceptibility testing of Candida isolates.

Authors:  M Arendrup; B Lundgren; I M Jensen; B S Hansen; N Frimodt-Møller
Journal:  J Antimicrob Chemother       Date:  2001-05       Impact factor: 5.790

Review 2.  Development of interpretive breakpoints for antifungal susceptibility testing: conceptual framework and analysis of in vitro-in vivo correlation data for fluconazole, itraconazole, and candida infections. Subcommittee on Antifungal Susceptibility Testing of the National Committee for Clinical Laboratory Standards.

Authors:  J H Rex; M A Pfaller; J N Galgiani; M S Bartlett; A Espinel-Ingroff; M A Ghannoum; M Lancaster; F C Odds; M G Rinaldi; T J Walsh; A L Barry
Journal:  Clin Infect Dis       Date:  1997-02       Impact factor: 9.079

3.  Practice guidelines for the treatment of candidiasis. Infectious Diseases Society of America.

Authors:  J H Rex; T J Walsh; J D Sobel; S G Filler; P G Pappas; W E Dismukes; J E Edwards
Journal:  Clin Infect Dis       Date:  2000-04-20       Impact factor: 9.079

4.  Activities of fluconazole and voriconazole against 1,586 recent clinical isolates of Candida species determined by Broth microdilution, disk diffusion, and Etest methods: report from the ARTEMIS Global Antifungal Susceptibility Program, 2001.

Authors:  M A Pfaller; D J Diekema; S A Messer; L Boyken; R J Hollis
Journal:  J Clin Microbiol       Date:  2003-04       Impact factor: 5.948

5.  Quality control limits for broth microdilution susceptibility tests of ten antifungal agents.

Authors:  A L Barry; M A Pfaller; S D Brown; A Espinel-Ingroff; M A Ghannoum; C Knapp; R P Rennie; J H Rex; M G Rinaldi
Journal:  J Clin Microbiol       Date:  2000-09       Impact factor: 5.948

6.  Antifungal susceptibility testing of yeast isolates from blood cultures by microbroth dilution and the E test.

Authors:  A E Simor; G Goswell; L Louie; M Lee; M Louie
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1997-09       Impact factor: 3.267

7.  Evaluation of the Etest method for determining voriconazole susceptibilities of 312 clinical isolates of Candida species by using three different agar media.

Authors:  M A Pfaller; S A Messer; A Houston; K Mills; A Bolmstrom; R N Jones
Journal:  J Clin Microbiol       Date:  2000-10       Impact factor: 5.948

8.  A global evaluation of the susceptibility of Candida species to fluconazole by disk diffusion. Global Antifungal Surveillance Group.

Authors:  J Meis; M Petrou; J Bille; D Ellis; D Gibbs
Journal:  Diagn Microbiol Infect Dis       Date:  2000-04       Impact factor: 2.803

9.  Fluconazole and voriconazole multidisk testing of Candida species for disk test calibration and MIC estimation.

Authors:  G Kronvall; I Karlsson
Journal:  J Clin Microbiol       Date:  2001-04       Impact factor: 5.948

10.  Evaluation of the Etest method for determining fluconazole susceptibilities of 402 clinical yeast isolates by using three different agar media.

Authors:  M A Pfaller; S A Messer; A Karlsson; A Bolmström
Journal:  J Clin Microbiol       Date:  1998-09       Impact factor: 5.948

View more
  21 in total

1.  Correlation between microdilution, E-test, and disk diffusion methods for antifungal susceptibility testing of posaconazole against Candida spp.

Authors:  Charles R Sims; Victor L Paetznick; Jose R Rodriguez; Enuo Chen; Luis Ostrosky-Zeichner
Journal:  J Clin Microbiol       Date:  2006-06       Impact factor: 5.948

2.  Evaluation of Etest and disk diffusion methods compared with broth microdilution antifungal susceptibility testing of clinical isolates of Candida spp. against posaconazole.

Authors:  Daniel J Diekema; Shawn A Messer; Richard J Hollis; Linda B Boyken; Shailesh Tendolkar; Jennifer Kroeger; Michael A Pfaller
Journal:  J Clin Microbiol       Date:  2007-02-14       Impact factor: 5.948

3.  CHROMagar Candida medium for direct susceptibility testing of yeast from blood cultures.

Authors:  Grace L Tan; Ellena M Peterson
Journal:  J Clin Microbiol       Date:  2005-04       Impact factor: 5.948

4.  Comparison of results of voriconazole disk diffusion testing for Candida species with results from a central reference laboratory in the ARTEMIS global antifungal surveillance program.

Authors:  M A Pfaller; L Boyken; S A Messer; S Tendolkar; R J Hollis; D J Diekema
Journal:  J Clin Microbiol       Date:  2005-10       Impact factor: 5.948

5.  Antifungal susceptibility of 205 Candida spp. isolated primarily during invasive Candidiasis and comparison of the Vitek 2 system with the CLSI broth microdilution and Etest methods.

Authors:  N Bourgeois; L Dehandschoewercker; S Bertout; P-J Bousquet; P Rispail; L Lachaud
Journal:  J Clin Microbiol       Date:  2009-11-04       Impact factor: 5.948

6.  Use of fluconazole as a surrogate marker to predict susceptibility and resistance to voriconazole among 13,338 clinical isolates of Candida spp. Tested by clinical and laboratory standards institute-recommended broth microdilution methods.

Authors:  M A Pfaller; S A Messer; L Boyken; C Rice; S Tendolkar; R J Hollis; D J Diekema
Journal:  J Clin Microbiol       Date:  2006-11-01       Impact factor: 5.948

7.  In vitro activity of voriconazole and other antifungal agents against clinical isolates of Candida glabrata and Candida krusei.

Authors:  M Drago; M M Scaltrito; G Morace
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2004-07-16       Impact factor: 3.267

8.  Comparison of the susceptibilities of Candida spp. to fluconazole and voriconazole in a 4-year global evaluation using disk diffusion.

Authors:  Kevin C Hazen; Ellen Jo Baron; Arnaldo Lopes Colombo; Corrado Girmenia; Aurora Sanchez-Sousa; Amalia del Palacio; Catalina de Bedout; David L Gibbs
Journal:  J Clin Microbiol       Date:  2003-12       Impact factor: 5.948

Review 9.  Voriconazole : a review of its use in the management of invasive fungal infections.

Authors:  Lesley J Scott; Dene Simpson
Journal:  Drugs       Date:  2007       Impact factor: 9.546

10.  Stability of Mueller-Hinton agar supplemented with glucose and methylene blue for disk diffusion testing of fluconazole and voriconazole.

Authors:  M A Pfaller; L Boyken; S A Messer; R J Hollis; D J Diekema
Journal:  J Clin Microbiol       Date:  2004-03       Impact factor: 5.948

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.